Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
LG Chem will receive totaling up to $95.5 million for the China rights
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey
Subscribe To Our Newsletter & Stay Updated
